AAM (@AccessibleMeds) header
AAM (@AccessibleMeds) profile picture

Association for Accessible Medicines promotes policies to ensure generic & biosimilar medicines are accessible to people who need them.

Washington, D.C.
Joined May 2011
Photo by AAM (@AccessibleMeds)Photo by AAM (@AccessibleMeds)Photo by AAM (@AccessibleMeds)Photo by AAM (@AccessibleMeds)Photo by AAM (@AccessibleMeds)Photo by AAM (@AccessibleMeds)Photo by AAM (@AccessibleMeds)Photo by AAM (@AccessibleMeds)Photo by AAM (@AccessibleMeds)Photo by AAM (@AccessibleMeds)
The Association for Accessible Medicines and its @BiosimsCouncil recognize the importance of strong and stable leadership at the @FDA. Confirmed leadership provides important continuity and direction for FDA staff and helps ensure the agency can effectively carry out its critical public health mission. We look forward to working with FDA leadership and staff to promote timely access to safe, effective, and more affordable generic and biosimilar medicines for American patients.
1
1
63
Generic competition generates billions in savings each year. This industry’s high-volume model enables lower-cost medicines to serve as a driving force for healthcare resilience and economic stability in the U.S. accessiblemeds.org/resources…
47
A stable U.S. generic medicines market leads to healthcare and economic resilience and sustained patient care. But an instable generics market can lead to drug shortages, which negatively impacts patient care. Learn more: accessiblemeds.org/resources…
64
The economics of the generics market have deteriorated, putting the industry’s sustainability at risk. This should concern policymakers, as it threatens healthcare stability, economic resilience, and national security. Learn more: accessiblemeds.org/resources…
68
In the U.S., what makes generics structurally different from brand medicines is not chemistry. It’s economics. Because of this, prioritizing generic and biosimilar medicines as a unique market is essential for sustainable patient access. Learn more: accessiblemeds.org/resources…
66
2026 data from AAM shows a complex system where the number of patents asserted in the U.S. can be more than 10 times that of other countries. The result? Delayed patient access to lower-cost medications and their embedded savings. Learn more: accessiblemeds.org/resources…
1
1
107
In 2025, generic & biosimilar medicines accounted for scarcely more than 1% of total spending on healthcare in the U.S. At the same time, these lower-cost prescription options accounted for 89% of ALL prescriptions filled in America. Learn more: accessiblemeds.org/resources…
1
88
The biosimilars market is rapidly growing! After 10 years in the U.S., we know biosimilar medicines have been used in over 3.8 billion days of patient therapy, with no clinically meaningful differences in safety or efficacy! Learn more: accessiblemeds.org/resources…
92
Talk about getting off to an impressive start—WOW! Our second day of #GRxBiosims began with a compelling keynote featuring Sarah Yim, M.D. Director, Office of Therapeutic Biologics and Biosimilars, Office of New Drugs, CDER, @FDA – which was moderated by Claire D’Abreu-Hayling, M.S., President Generics Development & Chief Scientific Officer, Sandoz. Also joining us on the mainstage this morning was Elizabeth Miller, PharmD , Associate Commissioner for Inspections and Investigations, OII, FDA. Thank you to all our speakers and attendees for getting things started off RIGHT this morning! We can’t wait to see what’s next! @BiosimsCouncil
2
2
334
Huge thanks to Scott Biggs, Director, Supplier Services, @IQVIA_global! Our #GRx+Biosims attendees were treated to an info and data-packed presentation today, on the global and U.S. outlook for generic and biosimilar medicines - which covered a wide range of trends and challenges. Your insights are always appreciated , Scott 👍
2
2
139
Talk about enough takeaways to stay inspired and motivated for months, if not years, to come! Thank you to Keren Haruvi, President of Sandoz North America, Sandoz Inc. and Balaji Prasad, M.D., Chief Strategy Officer, Alvotech for engaging in our Biosimilars Market Leaders Discussion moderated by the Biosimilars Council’s Executive Director, Alex Keeton. And much appreciation for our CEO’s Unplugged Pannel, which was moderated by AAM Board Chair Bob Hoffman and included Punit Patel, PharmD, President and Chief Executive Officer, Americas, Zydus Pharmaceuticals USA, Inc.; Michael Parden, Chief Executive Officer, B. Braun of America Inc.; Brandon Rockwell President, PAI Pharma; and Joel Rosenstack, President, Generics, U.S., Fresenius Kabi USA, LLC.
2
3
161
And just like that, #GRxBiosims has come to an end. 🎉 Thank you to our incredibly talented AAM events planning team, our knowledgeable speakers and panelists, and of course YOU— our energetic attendees! See you at GRx+Biosims 2027! grxbiosims.org
2
3
113
Generic drugs depend on an intricate, global supply network for sourcing active pharmaceutical ingredients and other essential materials. Achieving meaningful progress toward onshoring will therefore require a comprehensive approach that addresses all stages of the manufacturing process. A huge thanks to our most recent mainstage panel that discussed the complexity of the global supply chain for generic and biosimilar medicines. Kudos to Christine Baeder, MBA, President, Apotex Corp.; Brooke Courtney, JD, MPH , Senior Regulatory Counsel, Office of Counterterrorism and Emerging Threats, Office of the Commissioner, FDA; Arlene Joyner, MS, PMP, CSSGB, Director, Center for Industrial Base Management and Supply Chain, Administration for Strategic Preparedness and Response (ASPR); Ronald T. Piervincenzi, PhD, Chief Executive Officer, U.S. Pharmacopeia (USP) and our moderator, AAM’s own Scott Kuzner, PhD, Senior Director, Sciences and Regulatory Affairs, AAM. We loved learning from you all! @USPharmacopeia @BiosimsCouncil
2
3
156
We are grateful for every attendee, speaker and sponsor who made GRx+Biosims 2026 GREAT! Thank you all for joining, engaging and sharing knowledge with us. Check out this event recap, and make your plans early to come back again next year: accessiblemeds.org/resources… @BiosimsCouncil
1
1
160
And just like that, #GRxBiosims has come to an end. 🎉 Thank you to our incredibly talented AAM events planning team, our knowledgeable speakers and panelists, and of course YOU— our energetic attendees! See you at GRx+Biosims 2027! grxbiosims.org
2
3
113
Talk about enough takeaways to stay inspired and motivated for months, if not years, to come! Thank you to Keren Haruvi, President of Sandoz North America, Sandoz Inc. and Balaji Prasad, M.D., Chief Strategy Officer, Alvotech for engaging in our Biosimilars Market Leaders Discussion moderated by the Biosimilars Council’s Executive Director, Alex Keeton. And much appreciation for our CEO’s Unplugged Pannel, which was moderated by AAM Board Chair Bob Hoffman and included Punit Patel, PharmD, President and Chief Executive Officer, Americas, Zydus Pharmaceuticals USA, Inc.; Michael Parden, Chief Executive Officer, B. Braun of America Inc.; Brandon Rockwell President, PAI Pharma; and Joel Rosenstack, President, Generics, U.S., Fresenius Kabi USA, LLC.
2
3
161
Huge thanks to Scott Biggs, Director, Supplier Services, @IQVIA_global! Our #GRx+Biosims attendees were treated to an info and data-packed presentation today, on the global and U.S. outlook for generic and biosimilar medicines - which covered a wide range of trends and challenges. Your insights are always appreciated , Scott 👍
2
2
139
A pleasure to have Lowell M. Zeta , J.D., Acting Chief of Staff, Office of the Commissioner, @FDA join Maryll Weatherston Toufanian , JD, Senior Vice President, Regulatory Strategy and Government Affairs, @AmnealPharma on our #GRx+Biosims mainstage this morning—for a highly insightful conversation on how the FDA and industry are working to evolve and adapt amid the complexities of the policy, regulatory and heath system spheres.
3
2
186
Welcome back! AAM Board Chair, Bob Hoffman, started off Day Three of #GRxBiosims with a compelling keynote that praised our sector—but his remarks also came with a warning. “We are the only segment of healthcare that consistently lowers costs for patients. But we are now experiencing sustained, downward economic pressure that threatens the long‑term viability of the entire generics market. Generic medicines face persistent price deflation year after year, even as the broader healthcare system exists in an inflationary state. This means as everything else in healthcare becomes more expensive, the cost of generic medicines continues to fall. This a problem. And none of us should be taking it lightly.”
1
1
82
A pleasure to have Lowell M. Zeta , J.D., Acting Chief of Staff, Office of the Commissioner, @FDA join Maryll Weatherston Toufanian , JD, Senior Vice President, Regulatory Strategy and Government Affairs, @AmnealPharma on our #GRx+Biosims mainstage this morning—for a highly insightful conversation on how the FDA and industry are working to evolve and adapt amid the complexities of the policy, regulatory and heath system spheres.
3
2
186